Patients exhibiting AD biomarkers of low Aβ and high t-tau in CSF and presymptomatic patients with PSEN1 mutation, all showed lower content of mtDNA in CSF compared to controls. This evidence concerns the gene PSEN1 and Alzheimer disease.